Stratec Biomedical (SBS) Given a €59.00 Price Target at Berenberg Bank

Stratec Biomedical (ETR:SBS) has been assigned a €59.00 ($70.24) target price by Berenberg Bank in a report released on Thursday. The brokerage presently has a “neutral” rating on the stock. Berenberg Bank’s price target would suggest a potential downside of 13.74% from the company’s previous close.

SBS has been the subject of a number of other reports. Oddo Bhf set a €58.00 ($69.05) price objective on Stratec Biomedical and gave the stock a “neutral” rating in a report on Monday, October 23rd. Kepler Capital Markets set a €70.00 ($83.33) price target on shares of Stratec Biomedical and gave the stock a “buy” rating in a research report on Friday, October 27th. Deutsche Bank set a €56.00 ($66.67) price target on shares of Stratec Biomedical and gave the stock a “neutral” rating in a research report on Tuesday, October 24th. Finally, Warburg Research set a €62.00 ($73.81) price target on shares of Stratec Biomedical and gave the stock a “buy” rating in a research report on Thursday, October 26th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of €60.50 ($72.02).

Shares of Stratec Biomedical (SBS) opened at €68.40 ($81.43) on Thursday. Stratec Biomedical has a twelve month low of €41.30 ($49.17) and a twelve month high of €69.85 ($83.15).

COPYRIGHT VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/07/stratec-biomedical-sbs-given-a-59-00-price-target-at-berenberg-bank.html.

About Stratec Biomedical

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply